Fully automated and super-rapid system for the detection of JAK2V617F mutation

Leukemia Research

Volumn 32, Issue 9, 2008, Pages 1462-1467

  Tanaka, Ruriko ^a   Kuroda, Junya ^b   Stevenson, William ^c   Ashihara, Eishi ^a   Ishikawa, Takayuki ^d   Taki, Tomohiko ^b   Kobayashi, Yutaka ^e   Kamitsuji, Yuri ^a,b   Kawata, Eri ^a,b   Takeuchi, Miki ^a   Murotani, Yoshihide ^a   Yokota, Asumi ^a   Hirai, Mitsuharu ^f   Majima, Satoshi ^f   Taniwaki, Masafumi ^b   Maekawa, Taira ^a   Kimura, Shinya ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d KYOTO UNIVERSITY   (Japan)

^e KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^f ARKRAY Healthcare Pvt Ltd   (Japan)

Author keywords

Chronic myeloproliferative diseases; Direct sequencing; Guanine quenching probe; JAK2; V617F

Indexed keywords

CYTARABINE; DNA; GUANINE; JAK2V617F ENZYME; JANUS KINASE 2; MUTANT PROTEIN;

ADULT; AGED; ALLELE; AMPLICON; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DNA BINDING; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AUTOMATION; CHRONIC DISEASE; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; POLYMERASE CHAIN REACTION;

EID: 43049165922     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.12.019     Document Type: Article

References (8)

1. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematol Am Soc Hematol Educ Program (2006) 240-245
2. Li Z., Xu M., Xing S., et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 282 (2007) 3428-3432
3. Ito T., Tanaka H., and Kimura A. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol 78 (2007) 417-431
4. Vardiman J.W., Brunning R.D., and Harris N.L. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World health Organization classification of tumours: tumours of the haematopoietic and lymphoid tissues (2001), International Agency for Research on Cancer Press, Lyon, France 17-44
5. Matsumoto N., Kakihara F., Kimura S., et al. Single nucleotide polymorphism genotyping of CYP2C19 using a new automated system. Anal Biochem 370 (2007) 121-123
6. Stevenson W.S., Hoyt R., Bell A., et al. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. Pathology 38 (2006) 336-342
7. Poodt J., Fijnheer R., Walsh I.B., and Hermans M.H. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. Hematol Oncol 24 (2006) 227-233
8. Kimura S., Naito H., Segawa H., et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106 (2005) 3948-3954